Respiratorius AB (XSAT:RESP) Net Margin %: -15,745.45% (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

XSAT:RESP Respiratorius AB XSAT:RESP
33 GF Score
Price kr3.00
View Full Analysis

What is Respiratorius AB Net Margin %?

Respiratorius AB XSAT:RESP -7.69% 33 Net Margin % is -15,745.45% as of Mar. 2026. GuruFocus rates XSAT:RESP with a GF Score™ of 33/100. Among 941 Biotechnology companies, Respiratorius AB ranks worse than 95.54% on this metric.

Net margin is calculated as Net Income divided by its Revenue. Respiratorius AB's Net Income for the three months ended in Mar. 2026 was kr-1.73 Mil. Respiratorius AB's Revenue for the three months ended in Mar. 2026 was kr0.01 Mil. Therefore, Respiratorius AB's net margin for the quarter that ended in Mar. 2026 was -15,745.45%.

The historical rank and industry rank for Respiratorius AB's Net Margin % or its related term are showing as below:

XSAT:RESP' s Net Margin % Range Over the Past 10 Years
Min: -21545.16   Med: 0   Max: 0
Current: -21545.16

XSAT:RESP's Net Margin % is ranked worse than
95.54% of 941 companies
in the Biotechnology industry
Industry Median: -88.29 vs XSAT:RESP: -21545.16

Respiratorius AB  (XSAT:RESP) Net Margin % Explanation

Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.

But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.

Respiratorius AB Net Margin % Related Terms

Respiratorius AB Net Margin % Historical Data

* Premium members only.

The historical data trend for Respiratorius AB's Net Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Respiratorius AB Net Margin % Chart

Respiratorius AB Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Net Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Respiratorius AB Quarterly Data
Mar21 Jun21 Sep21 Dec21 Apr22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Net Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 -9,025.00 0.00 0.00 -15,745.45

XSAT:RESP vs VRTX, REGN, ALNY: Net Margin % Comparison

For the Biotechnology subindustry, Respiratorius AB's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Respiratorius AB Net Margin % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Respiratorius AB's Net Margin % distribution charts can be found below:

* The bar in red indicates where Respiratorius AB's Net Margin % falls into.


XSAT:RESP
33GF Score
Respiratorius AB XSAT:RESP
Net Margin % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Respiratorius AB Net Margin % Calculation

Net margin - also known as net profit margin is the ratio of Net Income divided by net sales or Revenue, usually presented in percent.

Respiratorius AB's Net Margin for the fiscal year that ended in Dec. 2025 is calculated as

Net Margin=Net Income (A: Dec. 2025 )/Revenue (A: Dec. 2025 )
=-6.953/0
= %

Respiratorius AB's Net Margin for the quarter that ended in Mar. 2026 is calculated as

Net Margin=Net Income (Q: Mar. 2026 )/Revenue (Q: Mar. 2026 )
=-1.732/0.011
=-15,745.45 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Net Margin % →
What does a Net Margin % of -15,745.45% mean?
Respiratorius AB (XSAT:RESP) has a Net Margin % of -15,745.45% as of Mar. 2026. Net margin is the ratio of total net income to net sales. View historical data on Respiratorius AB and its competitors. According to the industry distribution chart, Respiratorius AB ranks #899 out of 941 companies in the Biotechnology industry, placing it in the top 95.5%.
Is Respiratorius AB's Net Margin % too high?
Respiratorius AB's current Net Margin % is -15,745.45%. Based on the distribution chart, Respiratorius AB ranks #899 out of 941 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Respiratorius AB has a GF Score™ of 33/100, reflecting its overall financial health beyond just this single metric.
How does Respiratorius AB's Net Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Respiratorius AB ranks #899 out of 941 companies for Net Margin %. This places Respiratorius AB in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Margin % for a Biotechnology company?
A good Net Margin % depends on the Biotechnology industry context. However, Net Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Margin % mean?
A high Net Margin % can signal that a stock is expensive relative to its fundamentals. Net margin is the ratio of total net income to net sales. View historical data on Respiratorius AB and its competitors. Respiratorius AB's current Net Margin % is -15,745.45%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Respiratorius AB stock overvalued right now?
Respiratorius AB (XSAT:RESP) has a current Net Margin % of -15,745.45%. The current Net Margin % is -15,745.45%. Respiratorius AB's overall GF Score™ is 33/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Margin % calculated?
Net Margin % is calculated from a company's financial statements. For Respiratorius AB (XSAT:RESP), the current Net Margin % is -15,745.45% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Respiratorius AB Business Description

Address Scheelevagen 2, Medicon Village, Lund, SWE, 223 81
Respiratorius AB develops pharmaceutical drugs to treat the common diseases namely Cancer, Chronic Obstructive Pulmonary Disease (COPD), and asthma as well as better methods for diagnosing cardiovascular diseases. The company's drug candidates includes RCD405, VAL001, RESP2000, RESP3000, RESP9000, and RESP1000.
33GF Score

Get the complete analysis for XSAT:RESP

Net Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr3.00
Price